SAho mrt paopedr ified formula for calculating low-density lipoprotein cholesterol values

Lipids in Health and Disease

Volumn 9, Issue 1, 2010, Pages

  Chen, Yunqin ^a   Zhang, Xiaojin ^a   Pan, Baishen ^a   Jin, Xuejuan ^a   Yao, Haili ^a   Chen, Bin ^a   Zou, Yunzeng ^a   Ge, Junbo ^a   Chen, Haozhu ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ANALYTIC METHOD; ARTICLE; BLAND ALTMAN PLOT; CALCULATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; FRIEDEWALD FORMULA; HUMAN; HYPERTRIGLYCERIDEMIA; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MEASUREMENT ACCURACY; MODIFIED FRIEDEWALD FORMULA; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; EVALUATION; STANDARD; THEORETICAL MODEL;

CHOLESTEROL, LDL; HUMANS; HYPERTRIGLYCERIDEMIA; MODELS, THEORETICAL; TRIGLYCERIDES; WEIGHTS AND MEASURES; YOUNG ADULT;

EID: 77952433401     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-9-52     Document Type: Article

References (20)

1. Cheng AY, Leiter LA: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Curr Opin Cardiol 2006, 21:400-4.
2. National Cholesterol Education Program (NCEP) Expert Panel: Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002, 106:3143-421.
3. Keevil JG, Cullen MW, Gangnon R, McBride PE, Stein JH: Implications of cardiac risk and low-density lipoprotein cholesterol distributions in the United States for the diagnosis and treatment of dyslipidemia: data from National Health and Nutrition Examination Survey 1999 to 2002. Circulation 2007, 115:1363-70.
4. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972, 18:499-502.
5. McNamara JR, Cohn JS, Wilson PW, Schaefer EJ: Calculated values for low-density lipoprotein cholesterol in the assessment of lipid abnormalities and coronary disease risk. Clin Chem 1990, 36:36-42.
6. Abudu N, Levinson SS: Calculated low-density lipoprotein cholesterol remains a viable and important test for screening and targeting therapy. Clin Chem Lab Med 2007, 45:1319-25.
7. Nauck M, Warnick GR, Rifai N: Methods for measurement of LDLcholesterol: a critical assessment of direct measurement by homogeneous assays versus calculation. Clin Chem 2002, 48:236-54.
8. Lindsey CC, Graham MR, Johnston TP, Kiroff CG, Freshley A: A clinical comparison of calculated versus direct measurement of low-density lipoprotein cholesterol level. Pharmacotherapy 2004, 24:167-72.
9. Tighe DA, Ockene IS, Reed G, Nicolosi R: Calculated low density lipoprotein cholesterol levels frequently underestimate directly measured low density lipoprotein cholesterol determinations in patients with serum triglyceride levels or = 4.52 mmol/l: an analysis comparing the LipiDirect magnetic LDL assay with the Friedewald calculation. Clin Chim Acta 2006, 365:236-42
10. Rubias-Prat J, Reverter JL, Senta M, Pedro-Botet J, Salinas I, Lucas A, Noguas X, Sanmarta A: Calculated low-density lipoprotein cholesterol should not be used for management of lipoprotein abnormalities in patients with diabetes mellitus. Diabetes Care 1993, 16:1081-6.
11. Gazi I, Tsimihodimos V, Filippatos TD, Saougos VG, Bairaktari ET, Tselepis AD, Elisaf M: LDL cholesterol estimation in patients with the metabolic syndrome. Lipids Health Dis 2006, 5:8.
12. Wagner AM, Zapico E, Bonet R, Parez A, Ordaaez-Llanos J: The effect of VLDL particles on the accuracy of a direct LDL-cholesterol method in type 2 diabetic patients. Clin Biochem 2003, 36:177-83.
13. Planella T, Cortas M, Martanez-Bra C, Gonzalez-Sastre F, Ordaaez-Llanos J: Calculation of LDL-cholesterol by using apolipoprotein B for classification of nonchylomicronemic dyslipemia. Clin Chem 1997, 43:808-15.
14. Hattori Y, Suzuki M, Tsushima M, Yoshida M, Tokunaga Y, Wang Y, Zhao D, Takeuchi M, Hara Y, Ryomoto KI, Ikebuchi M, Kishioka H, Mannami T, Baba S, Harano Y: Development of approximate formula for LDL-chol, LDLapo B and LDL-chol/LDL-Apo B as indices of hyperapobetalipoproteinemia and small dense LDL. Atherosclerosis 1998, 138:289-99.
15. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E: High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001, 358:2026-33.
16. Miller M, Ginsberg HN, Schaefer EJ: Relative atherogenicity and predictive value of non-high-density lipoprotein cholesterol for coronary heart disease. Am J Cardiol 2008, 101:1003-8.
17. Esteban-Salan M, Guiman-Bardesi A, de La Viuda-Unzueta JM, Azcarate-Ania MN, Pascual-Usandizaga P, Amoroto-Del-Rao E: Analytical and clinical evaluation of two homogeneous assays for LDL-cholesterol in hyperlipidemic patients. Clin Chem 2000, 46(8 Pt 1):1121-31.
18. Bland JM, Altman DG: Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986, 1(8476):307-310.
19. Cordova CM, Schneider CR, Juttel ID, Cordova MM: Comparison of LDLcholesterol direct measurement with the estimate using the Friedewald formula in a sample of 10,664 patients. Arq Bras Cardiol 2004, 83:482-7.
20. Ran Jun K, Park HI, Chun S, Park H, Min WK: Effects of total cholesterol and triglyceride on the percentage difference between the lowdensity lipoprotein cholesterol concentration measured directly and calculated using the Friedewald formula. Clin Chem Lab Med 2008, 46:371-5.